tiprankstipranks
Crinetics initiated with a Buy at TD Cowen
The Fly

Crinetics initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Crinetics (CRNX) with a Buy rating and no price target The firm says Crinetics is “revered” in the endocrine space with a pipeline that has the potential to generate tens of billions of sales. Paltusotine should be approved in September and become the standard of care for acromegaly and carcinoid syndrome, the analyst tells investors in a research note. TD also views the company’s early-stage pipeline as “impressive and robust.”

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App